2019
AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
Fan Z, Cheng H, Jin K, Gong Y, Huang Q, Xu J, Ni Q, Yu X, Liu C, Luo G. AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. World Journal Of Surgical Oncology 2019, 17: 137. PMID: 31387646, PMCID: PMC6685146, DOI: 10.1186/s12957-019-1682-9.Peer-Reviewed Original ResearchConceptsInvasive IPMNInvasive intraductal papillary mucinous neoplasmStage IB diseaseStage IIA diseaseHazard ratioEdition classificationIIA diseaseIB diseaseStaging classificationStaging systemEnd Results cancer registryIntraductal papillary mucinous neoplasmEdition staging systemPredictors of survivalAmerican Joint CommitteeCancer (AJCC) staging systemPapillary mucinous neoplasmConclusionsThe AJCCResectable tumorsAJCC stagingStage IIACancer RegistryTumor sizeMucinous neoplasmsResultsIn total
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2015
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinoma
2014
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
Wang W, Liu L, Xu H, Sun H, Wu C, Zhu X, Zhang W, Xu J, Liu C, Long J, Ni Q, Tang Z, Yu X. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget 2014, 5: 3895-3906. PMID: 25008315, PMCID: PMC4116529, DOI: 10.18632/oncotarget.2019.Peer-Reviewed Original ResearchConceptsSurvival of hepatocellular carcinomaMicrovessel densityHepatocellular carcinomaSorafenib treatmentDissemination of hepatocellular carcinomaAssociated with inhibition of angiogenesisAdvanced hepatocellular carcinomaMicrovessel density valuesCurative HCC resectionSuppressor of tumor growthInhibition of angiogenesisNegative prognostic indicatorAssociated with inhibitionSorafenib interventionHCC resectionSorafenib administrationOverall survivalDisease recurrencePrognostic factorsTissue microarrayPrognostic indicatorTumor growthSorafenibPersonalized treatmentPredictive valueMetabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting overall survivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis
2012
Hepatocyte Paraffin 1 Antigen as a Biomarker for Early Diagnosis of Barrett Esophagus
Jeung J, Coran J, Liu C, Cardona D. Hepatocyte Paraffin 1 Antigen as a Biomarker for Early Diagnosis of Barrett Esophagus. American Journal Of Clinical Pathology 2012, 137: 111-120. PMID: 22180484, PMCID: PMC3806975, DOI: 10.1309/ajcpyobvgs4cga8y.Peer-Reviewed Original ResearchConceptsBarrett's esophagusBE casesMorphologic changesIntestinal differentiationReflux esophagitis casesSmall intestinal differentiationMetaplastic reactionCertain morphologic changesClinicopathologic featuresIntestinal metaplasiaAntigen expressionEarly diagnosisSensitive markerBiopsy casesGoblet cellsMorphologic featuresRE casesEsophagusExpressionMetaplasiaHepPar1CasesInjuryAntigenDiagnosis
2009
Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25). Digestive Diseases And Sciences 2009, 55: 484-495. PMID: 19714465, PMCID: PMC3161029, DOI: 10.1007/s10620-009-0955-5.Peer-Reviewed Original ResearchConceptsT cell responsesHCC patientsHepatocellular carcinomaCell responsesTumor burdenImpaired T cell responsesLower IFN-γ productionEffector T cell responsesIL-2 receptor alpha chainATP production assaysLevels of sCD25Tolerogenic tumor environmentIFN-γ ELISPOTEffector T cellsT cell immunityT cell reactivityIFN-γ productionIL-2 supplementationT cell defectsDose-dependent mannerReceptor alpha chainIL-2 signalingSerum sCD25Soluble CD25Worse survivalIdentification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland
Vila L, Liu H, Al-Quran S, Coco D, Dong H, Liu C. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Modern Pathology 2009, 22: 1296-1302. PMID: 19617878, PMCID: PMC3746033, DOI: 10.1038/modpathol.2009.95.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Adenoid CysticDNA Mutational AnalysisExonsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedMutation, MissensePoint MutationPolymerase Chain ReactionProto-Oncogene Proteins c-kitSalivary Gland Neoplasms
2006
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum
Winfield R, Hochwald S, Vogel S, Hemming A, Liu C, Cance W, Grobmyer S. Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum. The American Surgeon 2006, 72: 719-723. PMID: 16913316, DOI: 10.1177/000313480607200811.Peer-Reviewed Original ResearchConceptsDuodenal gastrointestinal stromal tumorGastrointestinal stromal tumorsSmall bowel gastrointestinal stromal tumorsGastric gastrointestinal stromal tumorsStromal tumorsPartial duodenal resectionHistory of neurofibromatosisPortion of duodenumDuodenal resectionGastrointestinal bleedingMedian sizeAdjuvant therapyCommon presentationComplete resectionRetrospective reviewSmall bowelRare tumorCase reportSingle institutionIncidental findingPatientsPancreaticoduodenectomyResectionTumorsDuodenum